Gilead, Glympse partner to assess NASH treatment response in trials

Gilead Sciences announced a strategic collaboration with Glympse Bio for clinical development of nonalcoholic steatohepatitis therapy, according to a press release.The collaboration includes Glympse Bio’s proprietary synthetic biomarkers, which will be used to identify NASH stage and disease progression and for early detection of treatment response in participants of Gilead’s clinical trials.“We are excited about the opportunity to partner with Glympse Bio to help inform our NASH development program,” Mani Subramanian, MD, PhD, senior vice president of liver diseaseRead More

Share on facebook
Share on twitter
Share on linkedin